Zenith Capital Corp. (ZHCLF)
USD 0.05
(-50.0%)
USD 0.05
(-50.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 10.06 Thousand USD | 128.62% |
| 2022 | 4402.00 USD | 26.82% |
| 2021 | 3471.00 USD | 31.13% |
| 2020 | 2647.00 USD | 605.87% |
| 2019 | 375.00 USD | 280.29% |
| 2018 | -208.00 USD | 82.13% |
| 2017 | -1164.00 USD | 88.56% |
| 2016 | -10.17 Thousand USD | -2736.01% |
| 2015 | 386.00 USD | 310.64% |
| 2014 | 94.00 USD | 108.17% |
| 2013 | -1151.00 USD | -115.25% |
| 2012 | 7549.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 11.68 Thousand USD | 16.09% |
| 2023 Q1 | 4764.00 USD | 8.22% |
| 2023 Q2 | 6098.00 USD | 28.0% |
| 2023 Q4 | 10.06 Thousand USD | 17.97% |
| 2023 Q3 | 8531.00 USD | 39.9% |
| 2022 Q3 | 3768.00 USD | 30.38% |
| 2022 Q4 | 4402.00 USD | 16.83% |
| 2022 FY | 4402.00 USD | 26.82% |
| 2022 Q1 | 3924.00 USD | 13.05% |
| 2022 Q2 | 2890.00 USD | -26.35% |
| 2021 Q3 | 3223.00 USD | -1.04% |
| 2021 Q2 | 3257.00 USD | 20.01% |
| 2021 FY | 3471.00 USD | 31.13% |
| 2021 Q4 | 3471.00 USD | 7.69% |
| 2021 Q1 | 2714.00 USD | 2.53% |
| 2020 Q4 | 2647.00 USD | 286.99% |
| 2020 Q1 | 811.00 USD | 116.27% |
| 2020 FY | 2647.00 USD | 605.87% |
| 2020 Q2 | 307.00 USD | -62.15% |
| 2020 Q3 | 684.00 USD | 122.8% |
| 2019 FY | 375.00 USD | 280.29% |
| 2019 Q4 | 375.00 USD | 132.44% |
| 2019 Q3 | -1156.00 USD | -358.73% |
| 2019 Q2 | -252.00 USD | 67.4% |
| 2019 Q1 | -773.00 USD | -271.63% |
| 2018 Q2 | -2054.00 USD | -28.29% |
| 2018 Q3 | -83.00 USD | 95.96% |
| 2018 Q4 | -208.00 USD | -150.6% |
| 2018 FY | -208.00 USD | 82.13% |
| 2018 Q1 | -1601.00 USD | -37.54% |
| 2017 Q4 | -1164.00 USD | 59.96% |
| 2017 FY | -1164.00 USD | 88.56% |
| 2017 Q3 | -2907.00 USD | 44.58% |
| 2017 Q2 | -5245.00 USD | 29.32% |
| 2017 Q1 | -7421.00 USD | 27.07% |
| 2016 Q4 | -10.17 Thousand USD | 12.16% |
| 2016 FY | -10.17 Thousand USD | -2736.01% |
| 2016 Q1 | -15.31 Thousand USD | -4068.65% |
| 2016 Q2 | -13.24 Thousand USD | 13.53% |
| 2016 Q3 | -11.58 Thousand USD | 12.55% |
| 2015 Q2 | -68.00 USD | 93.27% |
| 2015 Q1 | -1011.00 USD | -1175.53% |
| 2015 Q4 | 386.00 USD | 278.43% |
| 2015 FY | 386.00 USD | 310.64% |
| 2015 Q3 | 102.00 USD | 250.0% |
| 2014 Q3 | -201.00 USD | 49.11% |
| 2014 Q2 | -395.00 USD | 48.63% |
| 2014 Q1 | -769.00 USD | 33.19% |
| 2014 Q4 | 94.00 USD | 146.77% |
| 2014 FY | 94.00 USD | 108.17% |
| 2013 Q4 | -1151.00 USD | 43.96% |
| 2013 FY | -1151.00 USD | -115.25% |
| 2013 Q3 | -2054.00 USD | 50.66% |
| 2013 Q2 | -4163.00 USD | 49.36% |
| 2013 Q1 | -8221.00 USD | -208.9% |
| 2012 FY | 7549.00 USD | 0.0% |
| 2012 Q4 | 7549.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.976% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 98.383% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 104.032% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 149.314% |
| Qrons Inc. | 351.42 Thousand USD | 97.136% |
| Rebus Holdings, Inc. | 305 Thousand USD | 96.7% |
| Skye Bioscience, Inc. | -5.72 Million USD | 100.176% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 100.16% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.977% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 49.343% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 99.822% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 868.244% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.936% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 99.756% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 97.496% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.028% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 99.551% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 98.915% |
| Mesoblast Limited | 55.85 Million USD | 99.982% |
| Marizyme, Inc. | 18.56 Million USD | 99.946% |
| Genus plc | 190.6 Million USD | 99.995% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 99.55% |
| Pharming Group N.V. | 109.8 Million USD | 99.991% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 98.83% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 99.171% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 98.52% |
| ContraFect Corporation | -6.02 Million USD | 100.167% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 92.525% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 99.129% |
| IMV Inc. | 7.67 Million USD | 99.869% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 99.817% |
| MultiCell Technologies, Inc. | 90.04 USD | -11077.255% |
| ONE Bio Corp. | 9.04 Million USD | 99.889% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 101.371% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 99.922% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 99.264% |
| Q BioMed Inc. | 4.06 Million USD | 99.752% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.967% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 99.001% |
| Biomind Labs Inc. | 711.4 Thousand USD | 98.585% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.983% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 99.497% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 99.921% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 97.202% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 92.801% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 99.543% |
| GB Sciences, Inc. | 1.74 Million USD | 99.424% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 105.476% |
| HST Global, Inc. | 96.79 Thousand USD | 89.603% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 95.12% |
| Halberd Corporation | 144.72 Thousand USD | 93.046% |
| Enzolytics Inc. | 981.65 Thousand USD | 98.975% |
| Agentix Corp. | 37.63 Thousand USD | 73.256% |
| Resverlogix Corp. | 6.45 Million USD | 99.844% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 101.495% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.021% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.858% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 99.628% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 100.114% |
| AVAX Technologies, Inc. | -5.9 Million USD | 100.17% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.001% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 94.979% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 99.578% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 93.882% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 154.94% |
| Kadimastem Ltd | -253.1 Thousand USD | 103.976% |
| Helix BioMedix, Inc. | -2.57 Million USD | 100.392% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.95% |
| BioStem Technologies, Inc. | 4.47 Million USD | 99.775% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 94.999% |
| LadRx Corporation | -2.03 Million USD | 100.494% |
| Cell Source, Inc. | 9.23 Million USD | 99.891% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 98.416% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 98.416% |
| NovAccess Global Inc. | 2.17 Million USD | 99.538% |
| Affymax, Inc. | -5.59 Million USD | 100.18% |
| Itoco Inc. | 228.3 Thousand USD | 95.592% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 92.599% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 99.797% |
| Mobile Lads Corp. | 484.23 Thousand USD | 97.922% |
| CytoDyn Inc. | 20.26 Million USD | 99.95% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1655.487% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 208.585% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 99.869% |
| SYBLEU INC | 473.71 Thousand USD | 97.876% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 99.774% |
| International Stem Cell Corporation | 2.59 Million USD | 99.611% |
| Bioxytran, Inc. | 1.89 Million USD | 99.47% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 83.875% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 99.539% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 99.707% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 99.882% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 98.697% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 100.805% |
| Neutra Corp. | 52.18 Thousand USD | 80.716% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 100.404% |
| PureTech Health plc | -167.19 Million USD | 100.006% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 104.109% |
| IXICO plc | -4.44 Million USD | 100.226% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 99.924% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.982% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 100.023% |